论文部分内容阅读
将诱变的αＣＤ３杂交瘤（ＴＫ~－）与ＰＤ４杂交瘤（ＨＧＰＲＴ~－）融合，获得分泌双功能抗体（ＢｓＡｂ）的四体杂交瘤Ｃ３．ＢｓＡｂＣ３可分别与ＣＤ３分子及胃癌相关抗原Ｐ４０反应．体外杀伤试验证实，当效靶比为４０：１，ＢｓＡｂＣ３浓度为１ｍｇ／Ｌ时，其杀伤效应可达７７．６％．该杀伤效应具有明显的特异性，仅Ｐ４０阳性表达的靶细胞可被溶解，体内杀伤试验证实，裸鼠接种胃癌细胞后５ｄ，以ＢｓＡｂＣ３活化的外周血淋巴细胞（ＰＢＬｓ）经局部皮下注射处理，可使移植胃癌完全消退（５／５）．这一明显的治疗作用可能与局部注射途径有关，可供临床应用参考．
The mutagenized αCD3 hybridoma (TK~-) was fused with a PD4 hybridoma (HGPRT~-) to obtain a bispecific hybridoma (BsAb)-secreting hybridoma C3. BsAbC3 reacts with CD3 and gastric cancer-associated antigen P40, respectively. The in vitro killing test confirmed that when the effective target ratio was 40:1 and BsAbC3 concentration was 1 mg/L, the killing effect was 77.6%. The killing effect has obvious specificity. Only the target cells positively expressed by P40 can be dissolved. In vivo killing experiments confirmed that 5 days after inoculation of gastric cancer cells in nude mice, peripheral blood lymphocytes (PBLs) activated by BsAbC3 were treated by local subcutaneous injection. Can completely eliminate the transplant gastric cancer (5/5). This obvious therapeutic effect may be related to the local injection route for clinical application.